These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19623638)

  • 21. Creatinine and cystatin C-based evaluation of renal function among obese subjects in Benin City, Nigeria.
    Alaje AK; Adedeji TA; Adedoyin AR; Idogun SE
    Saudi J Kidney Dis Transpl; 2019; 30(3):648-654. PubMed ID: 31249229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Changes of serum creatine kinase levels in children with Duchenne muscular dystrophy].
    Sun SC; Peng YS; He JB
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):35-7. PubMed ID: 18289468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary prostaglandin metabolites as Duchenne muscular dystrophy progression markers.
    Takeshita E; Komaki H; Tachimori H; Miyoshi K; Yamamiya I; Shimizu-Motohashi Y; Ishiyama A; Saito T; Nakagawa E; Sugai K; Sasaki M
    Brain Dev; 2018 Nov; 40(10):918-925. PubMed ID: 30006121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gait deviations in Duchenne muscular dystrophy-Part 2. Statistical non-parametric mapping to analyze gait deviations in children with Duchenne muscular dystrophy.
    Goudriaan M; Van den Hauwe M; Simon-Martinez C; Huenaerts C; Molenaers G; Goemans N; Desloovere K
    Gait Posture; 2018 Jun; 63():159-164. PubMed ID: 29751322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Correlation of Skeletal and Cardiac Muscle Dysfunction in Duchenne Muscular Dystrophy.
    Posner AD; Soslow JH; Burnette WB; Bian A; Shintani A; Sawyer DB; Markham LW
    J Neuromuscul Dis; 2016; 3(1):91-99. PubMed ID: 27182492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Corticosteroids in Duchenne muscular dystrophy: impact on the motor function measure sensitivity to change and implications for clinical trials.
    Schreiber A; Brochard S; Rippert P; Fontaine-Carbonnel S; Payan C; Poirot I; Hamroun D; Vuillerot C;
    Dev Med Child Neurol; 2018 Feb; 60(2):185-191. PubMed ID: 28990163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients.
    Capitanio D; Moriggi M; Torretta E; Barbacini P; De Palma S; Viganò A; Lochmüller H; Muntoni F; Ferlini A; Mora M; Gelfi C
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):547-563. PubMed ID: 31991054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of growth in ambulatory males with Duchenne muscular dystrophy.
    West NA; Yang ML; Weitzenkamp DA; Andrews J; Meaney FJ; Oleszek J; Miller LA; Matthews D; DiGuiseppi C
    J Pediatr; 2013 Dec; 163(6):1759-1763.e1. PubMed ID: 24103921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Respiratory Care Received by Individuals With Duchenne Muscular Dystrophy From 2000 to 2011.
    Andrews JG; Soim A; Pandya S; Westfield CP; Ciafaloni E; Fox DJ; Birnkrant DJ; Cunniff CM; Sheehan DW;
    Respir Care; 2016 Oct; 61(10):1349-59. PubMed ID: 27507176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum creatinine level: a supplemental index to distinguish Duchenne muscular dystrophy from Becker muscular dystrophy.
    Zhang H; Zhu Y; Sun Y; Liang Y; Li Y; Zhang Y; Deng L; Wen X; Zhang C
    Dis Markers; 2015; 2015():141856. PubMed ID: 25852218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The natural history of the patients with Duchenne muscular dystrophy in Taiwan: A medical center experience.
    Liang WC; Wang CH; Chou PC; Chen WZ; Jong YJ
    Pediatr Neonatol; 2018 Apr; 59(2):176-183. PubMed ID: 28903883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of within- and between-subject variation of serum cystatin C and serum creatinine in children aged 2-13 years.
    Andersen TB; Erlandsen EJ; Frøkiaer J; Eskild-Jensen A; Brøchner-Mortensen J
    Scand J Clin Lab Invest; 2010 Feb; 70(1):54-9. PubMed ID: 20073673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated Myocardial Extracellular Volume Fraction in Duchenne Muscular Dystrophy.
    Starc JJ; Moore RA; Rattan MS; Villa CR; Gao Z; Mazur W; Jefferies JL; Taylor MD
    Pediatr Cardiol; 2017 Oct; 38(7):1485-1492. PubMed ID: 28762167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relationship of body habitus and respiratory function in Duchenne muscular dystrophy.
    Chew K; Carey K; Ho G; Mallitt KA; Widger J; Farrar M
    Respir Med; 2016 Oct; 119():35-40. PubMed ID: 27692145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Usefulness of creatinine and cystatin C in the assessment of renal function in chronic kidney disease and coexisting diseases].
    Niemczyk S; Piotrowska M; Szamotulska K
    Pol Merkur Lekarski; 2012 May; 32(191):313-7. PubMed ID: 22779339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Troponin I Levels Correlate with Cardiac MR LGE and Native T1 Values in Duchenne Muscular Dystrophy Cardiomyopathy and Identify Early Disease Progression.
    Voleti S; Olivieri L; Hamann K; Gordish-Dressman H; Spurney C
    Pediatr Cardiol; 2020 Aug; 41(6):1173-1179. PubMed ID: 32476037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy.
    Kim S; Zhu Y; Romitti PA; Fox DJ; Sheehan DW; Valdez R; Matthews D; Barber BJ;
    Neuromuscul Disord; 2017 Aug; 27(8):730-737. PubMed ID: 28645460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of Cystatin C for Estimating Glomerular Filtration Rate in Patients With Muscular Dystrophy.
    Kimura K; Morita H; Daimon M; Horio M; Kawata T; Nakao T; Hirokawa M; Kitao R; Watanabe D; Komori T; Nagata T; Takeda S; Komaki H; Segawa K; Nakajima T; Takenaka K; Komuro I
    Int Heart J; 2016 May; 57(3):386-8. PubMed ID: 27170475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Latent process model of the 6-minute walk test in Duchenne muscular dystrophy : A Bayesian approach to quantifying rare disease progression.
    Lennie JL; Mondick JT; Gastonguay MR
    J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):91-104. PubMed ID: 31960231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.